Business Context and Reporting Period
This Form 6-K filing by Evaxion A/S (Evaxion Biotech A/S) covers the month of December 2025, specifically dated December 10, 2025. The filing serves to incorporate by reference a Prospectus Supplement filed with the SEC regarding an offering of American Depositary Shares (ADSs) under an existing Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC.
Key Financial Metrics
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on capital raising activities. Key figures related to the offering include:
- Aggregate Offering Price: Up to $45,527,824.
- Previous Sales under Agreement: $4,472,175.80 of ADSs sold pursuant to the Sales Agreement under the prior ATM Prospectus.
- Share Structure: Each ADS represents 50 ordinary shares with a nominal value of DKK 0.25 per share.
Material Changes
The primary material change disclosed is the amendment and supplementation of the prospectus dated March 24, 2025 (the "Prior Prospectus"). The new Prospectus Supplement increases the scope of the offering under the Sales Agreement, amending the previously filed ATM Prospectus which related to an offer of up to $4,480,000 of ADSs. The filing incorporates this new supplement into various registration statements (Forms S-8, F-3, and F-1).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook regarding the company's operational performance. It explicitly states that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in jurisdictions where such an offer would be unlawful. The document references legal opinions regarding the validity of the Ordinary Shares represented by the ADSs as Exhibit 5.1.
Investor Verification Checklist
- Verify the total amount of ADSs sold under the Sales Agreement to date, noting the $4,472,175.80 previously sold and the new capacity up to $45,527,824.
- Review the full text of the Prospectus Supplement and the ATM Prospectus (dated March 24, 2025) for detailed terms of the offering.
- Confirm the legal validity of the Ordinary Shares by referencing the opinion of Mazanti-Andersen Advokatpartnerselskab filed as Exhibit 5.1.
- Check subsequent filings for actual sales volumes and proceeds realized from this specific offering.